Q1 EPS Estimate for Collegium Pharmaceutical Cut by Analyst

Key Points

• HC Wainwright cut its Q1 2026 EPS estimate for Collegium to $1.08 from $1.42 while retaining a Buy rating and a $60 price target.
• Collegium last reported EPS of $2.04, missing the $2.20 consensus, with revenue of $205.45M (vs. $206.36M expected) but revenue was up 12.9% year‑over‑year.
• Company insiders have recently sold shares and the stock trades around $32.50 (market cap ~$1.05B) versus an average analyst target of $53.40, highlighting a wide gap between market price and analyst expectations.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Collegium Pharmaceutical in a research note issued on Thursday, April 23rd. HC Wainwright analyst B. Folkes now anticipates that the specialty pharmaceutical company will post earnings of $1.08 per share for the quarter, down from their previous estimate of $1.42. HC Wainwright has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Collegium Pharmaceutical's current full-year earnings is $6.38 per share.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). The firm had revenue of $205.45 million for the quarter, compared to analysts' expectations of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. Collegium Pharmaceutical's revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.77 EPS.

Several other brokerages have also recently commented on COLL. Wall Street Zen cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, March 5th. Barclays dropped their target price on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an "overweight" rating for the company in a research report on Friday, January 9th. Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $53.40.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $32.50 on Monday. The company has a 50 day moving average of $36.81 and a 200 day moving average of $41.52. The stock has a market cap of $1.05 billion, a P/E ratio of 19.01 and a beta of 0.77. Collegium Pharmaceutical has a 12 month low of $26.16 and a 12 month high of $50.79. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the sale, the executive vice president directly owned 77,071 shares in the company, valued at $2,691,319.32. The trade was a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Scott Dreyer sold 49,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the sale, the executive vice president owned 71,770 shares of the company's stock, valued at approximately $2,900,225.70. The trade was a 41.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.85% of the company's stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently made changes to their positions in the business. James Investment Research Inc. lifted its holdings in shares of Collegium Pharmaceutical by 19.7% in the 1st quarter. James Investment Research Inc. now owns 7,110 shares of the specialty pharmaceutical company's stock worth $235,000 after acquiring an additional 1,170 shares during the last quarter. Peregrine Capital Management LLC bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth approximately $3,185,000. Louisiana State Employees Retirement System bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth approximately $463,000. Ritholtz Wealth Management lifted its holdings in shares of Collegium Pharmaceutical by 35.1% in the 1st quarter. Ritholtz Wealth Management now owns 8,283 shares of the specialty pharmaceutical company's stock worth $274,000 after acquiring an additional 2,150 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Collegium Pharmaceutical by 284.4% in the 1st quarter. SG Americas Securities LLC now owns 66,397 shares of the specialty pharmaceutical company's stock worth $2,196,000 after acquiring an additional 49,123 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.